Garry Menzel

Dr. Garry E.
Menzel is an Independent Non-Executive Director at Adaptimmune Therapeutics Plc, an Independent Director at Black Diamond Therapeutics, Inc., a Member-National Board at Epilepsy Foundation and a Principal at Royal College of Art.
He is on the Board of Directors at Roslin Cell Therapies Ltd., Adaptimmune Therapeutics Plc, Black Diamond Therapeutics, Inc. and Epilepsy Therapy Project.
Dr. Menzel was previously employed as an Operating Partner by GHO Capital Partners LLP, an Independent Director by Stoke Therapeutics, Inc., a Chief Executive Officer by TCR2 Therapeutics, Inc., a Chief Strategy Officer by Pronutria Biosciences, Inc., a Chief Financial Officer by DaVita HealthCare Partners, Inc., a Chief Operating Officer by Regulus Therapeutics, Inc., a Managing Director by Credit Suisse Group, a Research Assistant by Smithkline Beecham Plc, a Consultant by Bain & Co., Inc., a Managing Director by The Goldman Sachs Group, Inc., and a Director-Emeritus by Institute for Systems Biology.
He received his undergraduate degree from Imperial College London, an MBA from Stanford Graduate School of Business and a doctorate degree from the University of Cambridge.